Cipla PAT increases marginally in Q3FY18

Cipla reported its results for the quarter ended December 31, 2017 on Wednesday. The company's consolidated revenue for the quarter came in at Rs. 3,913.82 crore, registering 7.3% yoy increase. This was primarily driven by jump in revenue from new ventures and Pharmaceuticals segment by 46.6 per cent and 7.3 per cent, respectively.

EBITDA for the quarter rose by 20.8 per cent yoy to Rs. 818.66 crore with a corresponding margin expansion of 234 bps. EBITDA margin for the quarter stood at 20.9%. This margin expansion was aided by favourable movements in inventories.

The PAT for the quarter came in at Rs. 403.45 crore, yoy increase of 4.8 per cent. Decline in finance cost by 84.6 per cent was offset by jump in deprecation expenses by 102.7 per cent.

Strong momentum continues across key markets including India, South Africa among others; India recorded healthy double digit growth with South Africa delivering its highest ever quarter in terms of sales.

On Wednesday, the stock opened at Rs. 582.75 per share and touched an intraday low of Rs. 554.60 on the BSE.